Major drug maker tracks eczema Pill's Real-World performance
NCT ID NCT05391061
Summary
This study is monitoring the safety and effectiveness of Cibinqo tablets in people with moderate-to-severe atopic dermatitis (eczema) during routine medical care in Korea. About 1,100 participants aged 12 and older who are starting Cibinqo treatment will be followed for approximately one year. Researchers will collect information on side effects and how well the medication controls eczema symptoms in everyday use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Tower
RECRUITINGSeoul, 04631, South Korea
Conditions
Explore the condition pages connected to this study.